ELTP
ELITE PHARMS INCstockOTC
elite pharmaceuticals, inc. develops oral sustained and controlled release products. elite's strategy includes assisting partner companies in the life cycle management of products, to improve off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry. elite has four anda products partnered with tagi pharma; one anda has launched, two andas are in the process of a manufacturing site transfer and an additional anda is currently under review by the fda. elite also manufactures lodrane d® and receives royalties for lodrane d®, an allergy product partnered with ecr pharmaceuticals ("ecr"), a wholly owned subsidiary of hi-tech pharmacal ("hi-tech"). elite's lead pipeline products, eli-216, a once-daily abuse resistant oxycodone, and eli-154, a once-daily oxycodone, are novel sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provisio
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.24 | 2026-11-11 | +54.02% | 3.860 |
| 1M | 0.25 | 2026-10-19 | +47.41% | -0.374 |
| 3M | 0.30 | 2026-08-18 | +21.80% | -0.235 |
| 6M | 0.35 | 2026-05-18 | +6.99% | -0.075 |
| 1Y | 0.56 | 2025-11-18 | -34.41% | 0.312 |
| 2Y | 0.67 | 2024-11-18 | -44.43% | — |
| 5Y | 0.04 | 2021-11-18 | +860.13% | 0.212 |
ELITE PHARMS INC (OTC:ELTP) stock price today is $0.37, and today's volume is 1,080,937. ELTP is up 0.997% today. The 30 day average volume is 752,987. ELTP market cap is $394.89M with 1.07B shares outstanding.